BOLD - Audentes Therapeutics: Encouraging Progress In XLMTM Pipeline Continues To Evolve

Shares of Audentes Therapeutics (BOLD) have risen by over 130% since my initial recommendation a couple years back. However, peformance is slightly negative since my January 2018 update piece.

At ASGCT (American Society of Gene & Cell Therapy) meeting this year, the company unveiled impressive data from a clinical study in XLMTM including a video clip showing a young patient who prior to treatment could not even sit up (was on ventilator). After being treated with gene therapy candidate AT132, the child was shown playing with a toy (and essentially enjoying himself

Read more ...